Company / FCF Margin
NEKTAR THERAPEUTICS FCF Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-377.8%
FY2025
5-year range
-419.7% / -214.7%
FY2021-FY2025
Trend
-76.0%
vs FY2024
Sector context
#109 of 133
Health Care
What the data says
NEKTAR THERAPEUTICS's fcf margin of -377.8% is lower than 82% of companies in the Health Care sector (FY2025). FCF Margin has fluctuated over the past 10 years, ranging from -419.7% in FY2023 to 59.0% in FY2020.
Based on SEC 10-K filings.
-377.8% in FY2025 with a 5-year CAGR of -436.8%.
Improved from -419.7% to -377.8% over the past 2 years.
Health Care sector context is included.
FCF Margin over time
Growth rates
- 3-Year Change
- -41.4pp
- 5-Year Change
- -436.8pp
- 10-Year Change
- -
Sector benchmark
Bottom 18% in Health CareTop 82% of 133This company -377.8% Sector average -632.8%
▼
+40.3% above sector average
Key checks
Key Insights
- In FY2025, fcf margin decreased 76.0% year-over-year.
- Currently 255.0pp above the Health Care sector average.
- Peak fcf margin was recorded in FY2020.
- Lowest fcf margin in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -11.97 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -377.8% | -76.0% |
| FY2024 | -214.7% | +48.8% |
| FY2023 | -419.7% | -24.7% |
| FY2022 | -336.4% | +19.8% |
| FY2021 | -419.7% | -811.4% |
| FY2020 | 59.0% | +301.5% |
| FY2019 | -29.3% | +60.8% |
| FY2018 | -74.6% | +79.5% |
| FY2017 | -364.3% | -381.1% |
| FY2016 | -75.7% | -107.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026